Australian Industry Rejects Planned Tendering System For Off-Patent Drugs
Executive Summary
Plans to introduce a tendering system for off-patent medicines have been sharply criticized by originator and generic industry bodies in Australia, but proposals for a fully operational electronic prescribing and health record system have met with a warmer reception.
You may also be interested in...
Stability At Last For Drug Innovators And Pricing In Australia
The Australian government has promised not to implement any new therapeutic groups under the Pharmaceutical Benefits Scheme for the next five years, nor will it introduce any new pricing reforms without consulting the innovative drug industry first.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.